Vivo Bio Tech Ltd
Incorporated in 1987, Vivo Bio Tech
Ltd is engaged in service of CRO offering
Drug Development & Discovery Services
to Pharmaceutical & Biotech Companies[1]
- Market Cap ₹ 53.2 Cr.
- Current Price ₹ 24.0
- High / Low ₹ 43.4 / 20.4
- Stock P/E
- Book Value ₹ 42.0
- Dividend Yield 0.00 %
- ROCE 7.27 %
- ROE -2.26 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.57 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.30% over past five years.
- Promoter holding is low: 35.4%
- Company has a low return on equity of 2.24% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.65%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.79 | 28.58 | 34.13 | 47.00 | 55.83 | 55.35 | 51.78 | 51.39 | 51.62 | 44.88 | 46.67 | 52.57 | |
| 14.99 | 24.87 | 26.50 | 36.11 | 46.32 | 42.87 | 33.98 | 35.30 | 29.80 | 23.62 | 25.82 | 31.95 | |
| Operating Profit | 2.80 | 3.71 | 7.63 | 10.89 | 9.51 | 12.48 | 17.80 | 16.09 | 21.82 | 21.26 | 20.85 | 20.62 |
| OPM % | 15.74% | 12.98% | 22.36% | 23.17% | 17.03% | 22.55% | 34.38% | 31.31% | 42.27% | 47.37% | 44.68% | 39.22% |
| 0.95 | 0.89 | 0.40 | 0.13 | 0.01 | 0.05 | 0.08 | 0.09 | 0.04 | 0.04 | 4.80 | 0.44 | |
| Interest | 0.51 | 0.47 | 1.29 | 2.37 | 2.64 | 3.10 | 3.67 | 4.27 | 7.99 | 7.95 | 7.55 | 5.85 |
| Depreciation | 3.05 | 3.35 | 3.90 | 4.64 | 5.06 | 5.17 | 5.59 | 7.44 | 9.27 | 9.29 | 9.02 | 10.63 |
| Profit before tax | 0.19 | 0.78 | 2.84 | 4.01 | 1.82 | 4.26 | 8.62 | 4.47 | 4.60 | 4.06 | 9.08 | 4.58 |
| Tax % | -142.11% | -16.67% | 11.62% | 21.95% | -23.08% | -4.46% | 34.11% | 50.78% | 42.83% | 37.93% | 16.63% | 142.36% |
| 0.46 | 0.91 | 2.50 | 3.12 | 2.25 | 4.44 | 5.68 | 2.20 | 2.63 | 2.52 | 7.57 | -1.94 | |
| EPS in Rs | 0.49 | 0.97 | 2.67 | 3.17 | 1.82 | 3.45 | 4.23 | 1.54 | 1.76 | 1.69 | 4.41 | -0.87 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -148% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -23% |
| 3 Years: | -7% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.35 | 9.35 | 9.35 | 9.85 | 12.35 | 12.89 | 13.42 | 14.26 | 14.90 | 14.90 | 17.16 | 22.19 |
| Reserves | -0.18 | 0.73 | 3.25 | 9.48 | 14.93 | 20.15 | 29.13 | 32.88 | 36.97 | 39.49 | 61.02 | 71.03 |
| 5.69 | 16.91 | 27.06 | 25.11 | 21.67 | 22.09 | 28.73 | 65.24 | 60.17 | 70.83 | 51.80 | 63.92 | |
| 26.57 | 18.68 | 11.47 | 15.09 | 6.36 | 6.29 | 6.03 | 7.92 | 8.77 | 9.58 | 11.31 | 17.72 | |
| Total Liabilities | 41.43 | 45.67 | 51.13 | 59.53 | 55.31 | 61.42 | 77.31 | 120.30 | 120.81 | 134.80 | 141.29 | 174.86 |
| 19.57 | 23.35 | 28.37 | 27.47 | 29.82 | 31.63 | 48.69 | 91.81 | 85.51 | 77.01 | 84.88 | 119.66 | |
| CWIP | 0.07 | 0.04 | 2.96 | 3.94 | 0.07 | 0.15 | 0.32 | 0.87 | 1.90 | 9.21 | 12.84 | 4.81 |
| Investments | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 21.95 |
| 21.77 | 22.25 | 19.77 | 28.09 | 25.39 | 29.60 | 28.26 | 27.58 | 33.36 | 48.54 | 43.53 | 28.44 | |
| Total Assets | 41.43 | 45.67 | 51.13 | 59.53 | 55.31 | 61.42 | 77.31 | 120.30 | 120.81 | 134.80 | 141.29 | 174.86 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.13 | 8.73 | -5.65 | 11.11 | -0.79 | 7.72 | 14.10 | 16.43 | 14.73 | 15.83 | 11.83 | 34.93 | |
| -1.92 | -7.12 | -11.84 | -4.72 | -3.53 | -7.08 | -22.82 | -51.11 | -4.00 | -7.95 | -15.84 | -59.35 | |
| -0.89 | -0.32 | 6.83 | -3.43 | 0.70 | -0.18 | 8.83 | 35.04 | -11.20 | -7.56 | 3.90 | 24.57 | |
| Net Cash Flow | -0.68 | 1.29 | -10.67 | 2.96 | -3.62 | 0.46 | 0.11 | 0.37 | -0.47 | 0.32 | -0.11 | 0.15 |
| Free Cash Flow | 0.10 | 1.62 | -17.49 | 6.39 | -4.32 | 0.65 | -8.72 | -34.68 | 10.73 | 7.88 | -4.01 | -2.51 |
| CFO/OP | 78% | 232% | -70% | 110% | -13% | 60% | 96% | 116% | 77% | 82% | 67% | 173% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88.43 | 48.79 | 82.03 | 91.48 | 54.98 | 69.11 | 51.39 | 85.37 | 87.54 | 92.47 | 87.67 | 81.58 |
| Inventory Days | 557.61 | 169.23 | 204.47 | 289.48 | 255.75 | 451.13 | 672.29 | 312.99 | 429.70 | 831.44 | 491.08 | 365.90 |
| Days Payable | 814.41 | 362.93 | 242.14 | 304.36 | 152.08 | 166.72 | 70.37 | 74.02 | 50.68 | 100.49 | 61.78 | 80.81 |
| Cash Conversion Cycle | -168.38 | -144.91 | 44.36 | 76.61 | 158.65 | 353.52 | 653.31 | 324.35 | 466.56 | 823.42 | 516.97 | 366.67 |
| Working Capital Days | -351.66 | -128.73 | 21.28 | -11.88 | 37.66 | 42.47 | 37.22 | 17.97 | 48.93 | 73.93 | 111.53 | -22.22 |
| ROCE % | 4.67% | 5.97% | 12.39% | 15.17% | 9.55% | 14.14% | 19.44% | 9.52% | 11.22% | 10.12% | 9.42% | 7.27% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Workforce Number of Employees |
|
||||||||||
| Pre-clinical Research Facility Area Sq. Ft. |
|||||||||||
| Campus Size Acres |
|||||||||||
| Number of Supported Firms/Clients Count |
|||||||||||
| Annual Animal Production Capacity Numbers |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Jun - Newspaper advertisement - Notice of postal ballot & e-voting
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 12 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Jun - Newspaper publication of notice for special window for re-lodgement of transfer request of physical shares
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 8 Jun
-
Report On Re-Lodgement Of Transfer Requests Of Physical Shares
6 Jun - Reported nil re-lodgement requests for physical share transfers in May 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBTL is a full-service preclinical contract research organisation (CRO) and specific pathogen free (SPF) laboratory animal breeder offering drug development and discovery services to pharmaceutical and biotech companies world-wide in accordance with OECD – GLP having applicability in OECD member countries and is accredited by AAALAC International. VBTL offers services in the areas of in-vitro, in-vivo, toxicity studies, pharmacological investigations, etc.